NSE: AJANTPHARM | BSE: 532331

Expensive Performer

Download real time

2585.20 -120.90 (-4.47%)

25.82% Fall from 52W High

167.5K NSE+BSE Volume

NSE 02 May, 2025 3:31 PM (IST)

32,292.3

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Search Inside the pdf :

Ajanta Pharma Ltd.

01 May 2025

2585.20

-4.47%

Ajanta Pharma (HOLD): A New Dawn of Culture

Hold: Ajanta Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Mix set of earnings where sales/EBITDA/PAT reported 5%/3%/10% above estimates; EBITDA margin reported 60 bps below estimates

Ajanta Pharma Ltd.'s price crossed below 50Day SMA today

Ajanta Pharma Ltd.

31 Jan 2025

2585.20

-4.47%

Ajanta Pharma (SELL): Entering newer therapies to result in higher costs

Sell: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

AJP reported in-line earnings, sales were 3.6% below estimates, while EBITDA/PAT reported 1%/3% above our estimates

Ajanta Pharma Ltd.'s price crossed below 50Day SMA today

Ajanta Pharma Ltd.

30 Jan 2025

2585.20

-4.47%

India/Asia drive earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered a marginally better-than-expected performance in 3QFY25. It has continued to outperform in the Domestic Formulation (DF) market during this quarter.

Ajanta Pharma Ltd.'s price crossed below 50Day SMA today

Ajanta Pharma Ltd.

11 Dec 2024

2585.20

-4.47%

Ajanta Pharma (SELL): No incremental triggers; valuation expensive

Sell: Ajanta Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

At our virtual conference AJP said it is not looking to venture into newer therapies in India in the next 1-2 years due to hefty valuations

Ajanta Pharma Ltd.'s price crossed below 50Day SMA today

Ajanta Pharma Ltd.

11 Nov 2024

2585.20

-4.47%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

BOB Capital Markets Ltd. upgraded Ajanta Pharma Ltd. to Hold with a price target of 2795.0 on 01 May, 2025.

Ajanta Pharma Ltd.

28 Oct 2024

2585.20

-4.47%

Branded generics drive earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered in-line performance in 2QFY25. Asia/Africa (47% of sales) grew strongly at 32% YoY in 2QFY25 due to superior execution and partly on the low base of the past year.

BOB Capital Markets Ltd. upgraded Ajanta Pharma Ltd. to Hold with a price target of 2795.0 on 01 May, 2025.

Ajanta Pharma Ltd.

31 Jul 2024

2585.20

-4.47%

Ajanta Pharma

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Ajanta Pharma Ltd.'s price crossed below 50Day SMA today

Ajanta Pharma Ltd.

30 Jul 2024

2585.20

-4.47%

Branded generics drive earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered better-than-expected 1QFY25 performance, led by a superior show in the branded Africa segment, lower raw material costs, and controlled other expenses.